Helena J Janse van Rensburg (H J Janse van Rensburg)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 5

Top Topics

High Throughput

Tyrosine Kinase

Cell Proliferation

Top Venues

Proceedings of the National Academy of Sciences of the United States of America

British journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Helena J Janse van Rensburg, Zhihui Liu, Geoffrey Alan Watson, Zachary W Veitch, Daniel Shepshelovich, Anna Spreafico, Albiruni R Abdul Razak, Philippe L Bedard, Lillian L Siu, Lori Minasian, Aaron Richard Hansen
A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events. British journal of cancer (2023)
Helena J Janse van Rensburg, Pavlina Spiliopoulou, Lillian L Siu
Circulating Biomarkers for Therapeutic Monitoring of Anti-cancer Agents. The oncologist 27 (5) (2022)
Xiaowei Guo, Yihao Sun, Taha Azad, Helena J Janse van Rensburg, Jingjing Luo, Shuai Yang, Peng Liu, Zhongwei Lv, Meixiao Zhan, Ligong Lu, Yingqun Zhou, Xianjue Ma, Xiaoping Zhang, Xiaolong Yang, Lei Xue
Rox8 promotes microRNA-dependent yki messenger RNA decay. Proceedings of the National Academy of Sciences of the United States of America 117 (48) (2020)
Kazem Nouri, Taha Azad, Min Ling, Helena J Janse van Rensburg, Alexander Pipchuk, He Shen, Yawei Hao, Jianmin Zhang, Xiaolong Yang
Identification of Celastrol as a Novel YAP-TEAD Inhibitor for Cancer Therapy by High Throughput Screening with Ultrasensitive YAP/TAZ-TEAD Biosensors. Cancers 11 (10) (2019)
Taha Azad, Kazem Nouri, Helena J Janse van Rensburg, Sarah M Maritan, Liqing Wu, Yawei Hao, Tess Montminy, Jihang Yu, Prem Khanal, Lois M Mulligan, Xiaolong Yang
A gain-of-functional screen identifies the Hippo pathway as a central mediator of receptor tyrosine kinases during tumorigenesis. Oncogene 39 (2) (2019)